1311 related articles for article (PubMed ID: 11742283)
1. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
2. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
3. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
4. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
Haeberli G; Brönnimann M; Hunziker T; Müller U
Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
[TBL] [Abstract][Full Text] [Related]
5. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
6. Possible circadian variation of serum mast cell tryptase concentration.
Dugas-Breit S; Przybilla B; Schöpf P; Ruëff F
Allergy; 2005 May; 60(5):689-92. PubMed ID: 15813817
[TBL] [Abstract][Full Text] [Related]
7. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
8. Hymenoptera venom allergy.
Przybilla B; Ruëff F
J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
[TBL] [Abstract][Full Text] [Related]
9. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
10. Bee venom immunotherapy - how early is it effective?
Goldberg A; Confino-Cohen R
Allergy; 2010 Mar; 65(3):391-5. PubMed ID: 19839973
[TBL] [Abstract][Full Text] [Related]
11. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
Lerch E; Müller UR
J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496
[TBL] [Abstract][Full Text] [Related]
12. Deliberate hymenoptera sting challenge as a diagnostic tool in highly selected venom-allergic patients.
Goldberg A; Confino-Cohen R; Mekori YA
Ann Allergy Asthma Immunol; 1995 Jul; 75(1):30-2. PubMed ID: 7621057
[TBL] [Abstract][Full Text] [Related]
13. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
[TBL] [Abstract][Full Text] [Related]
15. Mastocytosis and insect venom allergy.
Bonadonna P; Zanotti R; Müller U
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
[TBL] [Abstract][Full Text] [Related]
16. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Körner M; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B
J Allergy Clin Immunol; 2009 Nov; 124(5):1047-54. PubMed ID: 19895993
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy against hymenoptera venom: report of ten patients].
Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
[TBL] [Abstract][Full Text] [Related]
18. Basophil sensitivity in patients not responding to venom immunotherapy.
Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
[TBL] [Abstract][Full Text] [Related]
19. [Rush hyposensitization with Hymenoptera venoms. Tolerance and results of therapy].
Przybilla B; Ring J; Griesshammer B; Braun-Falco O
Dtsch Med Wochenschr; 1987 Mar; 112(11):416-24. PubMed ID: 3816590
[TBL] [Abstract][Full Text] [Related]
20. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations.
Ruëff F; Wolf H; Schnitker J; Ring J; Przybilla B
Allergy; 2004 Jun; 59(6):589-95. PubMed ID: 15147443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
